The Medical Letter on Drugs and Therapeutics
Drugs for Irritable Bowel Syndrome
March 23, 2020 (Issue: 1594)Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant bowel symptom as IBS with constipation (IBS-C),...more
- AC Ford et al. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol 2018; 113(Suppl 2):1.
- AC Ford et al. Irritable bowel syndrome. N Engl J Med 2017; 376:2566.
- SL Eswaran et al. A randomized controlled trial comparing the low FODMAPS diet vs. modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol 2016; 111:1824.
- SJ Shepherd et al. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 2013; 108:707.
- JR Biesiekierski et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106:508.
- JR Biesiekierski et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145:320.
- J Dionne et al. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. Am J Gastroenterol 2018; 113:1290.
- C Zhou et al. Exercise therapy of patients with irritable bowel syndrome: a systematic review of randomized controlled trials. Neurogastroenterol Motil 2019; 31:e13461.
- E Johannesson et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011; 106:915.
- D Schumann et al. Effect of yoga in the therapy of irritable bowel syndrome: a systematic review. Clin Gastroenterol Hepatol 2016; 14:1720.
- D Schumann et al. Randomised clinical trial: yoga vs a low-FODMAP diet in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2018; 47:203.
- N Nagarajan et al. The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2015; 27:1002.
- S Merat et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010; 55:1385.
- ZZRM Weerts et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology 2020; 158:123.
- M Rajilić-Stojanović et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol 2015; 110:278.
- AC Ford et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109:1547.
- Probiotics revisited. Med Lett Drugs Ther 2013; 55:3.
- AC Ford et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol 2019; 114:21.
- HA Everitt et al. Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut 2019; 68:1613.
- L Ruepert et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; 8:CD003460.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019 November 6 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Drugs for depression. Med Lett Drugs Ther 2020; 62:25.
- YA Saito et al. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther 2019; 49:389.
- RW Chapman et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013; 108:1508.
- Lubiprostone (Amitiza) for irritable bowel syndrome with constipation. Med Lett Drugs Ther 2008; 50:53.
- DA Drossman et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29:329.
- FDA. Medical Review: Lubiprostone. Available at: http://bit.ly/338eu7d. Accessed March 12, 2020.
- Linaclotide (Linzess) for constipation. Med Lett Drugs Ther 2012; 54:91.
- S Rao et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107:1714.
- WD Chey et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107:1702.
- DM Brenner et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol 2018; 113:735.
- A Munjal et al. Update on pharmacotherapy for irritable bowel syndrome. Curr Gastroenterol Rep 2019; 21:25.
- WD Chey et al. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J Gastroenterol 2020; 115:281.
- In brief: tegaserod (Zelnorm) returns. Med Lett Drugs Ther 2019; 61:72.
- Rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea. Med Lett Drugs Ther 2015; 57:109.
- M Pimentel et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364:22.
- A Lembo et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2016; 151:1113.
- M Camilleri et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2015; 41:438.
- Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea. Med Lett Drugs Ther 2016; 58:4.
- AJ Lembo et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 2016; 374:242.
- In brief: pancreatitis with eluxadoline (Viberzi) in patients without a gallbladder. Med Lett Drugs Ther 2017; 59:70.
- Alosetron (Lotronex) revisited. Med Lett Drugs Ther 2002; 44:67.
- R Krause et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007; 102:1709.
- K Garsed et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014; 63:1617.
- K Tong et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol 2013; 6:344.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.